Evamist.com HCP– Evamist® transdermal profile (estradiol transdermal spray)

Evamist^® delivers efficacy with a low dose

As recommended by the FDA, estrogen should be used in the lowest dose for the shortest duration needed.¹ Evamist delivers a low dose of 17ß-estradiol sprayed on a small area of the forearm. Evamist has proven efficacy with low serum estradiol levels compared with other transdermal estrogen therapies.^2,3

The estrogen in Evamist is chemically synthesized from a plant source.³
This does not mean Evamist is safer or more effective than other
hormone therapies.

Not all transdermal products are created equal

Transdermal delivery of estrogen was an advancement in the delivery of hormone therapy. However, not all transdermal products are created equal, and other transdermal products have disadvantages. Take a look at patches for instance…they can^4-6:

Fall off
Have irregular change schedules (3, 4, or 7 days)
Lead to localized irritation of the skin
Get dirty
Leave sticky adhesive residue
Be felt on the skin and visible to others

And gels and lotion may^7-10:

Need to be touched with the hands
Cover entire arm or leg
Take a longer time to dry

Evamist spray is more discreet than even the smallest patch, with no-touch application

Simple spray dries in a median of 67 seconds^†3
No need to worry about patch peeling or adhesive residue³
Fits easily into her daily routine
Flexible titration with three dosing options in one applicator²

As reported in an experience study of 247 women using Evamist, 90 of whom had no prior estrogen use.³

†

Patients should let spray dry for at least 2 minutes before dressing and at least 30 minutes before washing.²

» References

Important Safety Information

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER, PROBABLE DEMENTIA and UNINTENTIONAL SECONDARY EXPOSURE TO ESTROGEN

See full prescribing information for complete boxed warning

Estrogen-Alone Therapy

•	There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
•	Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
•	The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT)
•	The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Estrogen Plus Progestin Therapy

•	Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
•	The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism, and myocardial infarction
•	The WHI estrogen plus progestin study reported increased risks of invasive breast cancer
•	The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Estrogens with or without progestins should be prescribed at the lowest effective doses for the shortest duration consistent with the treatment goals for the individual woman.

Unintentional Secondary Exposure

Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional secondary exposure to Evamist by women using this product. In most cases, the condition resolved with removal of Evamist exposure. Women should ensure that children do not come into contact with the site(s) where Evamist is applied. Healthcare providers should advise patients to strictly adhere to recommended instructions for use.

Evamist is an estrogen indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Evamist should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or history of these conditions; active or recent arterial thromboembolic disease; liver dysfunction or disease; or known or suspected pregnancy.

In a clinical trial with Evamist the most common side effects were headache, breast tenderness, nipple pain, nausea, back pain and nasopharyngitis

Please see full prescribing information for Evamist, including boxed warnings.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.